Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 451 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastroesophageal Reflux Disease(GERD) Clear all
Recruiting No phase listed Observational

Abbott Cephea Mitral Valve Disease Registry

NCT07069673
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Annulus Calcification, Mitral Valve Replacement, Transcatheter Valve Replacement
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 12:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

NCT00222079
View directory record Official record
Conditions
Gastro-esophageal Reflux
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
Douglas Trask
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 22, 2026, 12:23 PM EDT
Not listed Not applicable Interventional

Novel Endoluminal Clinical TreAtment of Reflux

NCT03090607
View directory record Official record
Conditions
GERD
Interventions
Aluvra™, Saline
Device · Drug
Lead sponsor
Impleo Medical Inc.
Industry
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 22, 2026, 12:23 PM EDT
Not listed No phase listed Observational

Mucosal Impedance Sleeve Gastrectomy

NCT04166461
View directory record Official record
Conditions
Gastroesophageal Reflux, Bariatric Surgery Candidate
Interventions
Not application, observational study
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 22, 2026, 12:23 PM EDT
Enrolling by invitation No phase listed Observational

Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device

NCT03103789
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
single catheter mucosal impedance testing, balloon assembly mucosal impedance testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Timeline
2014 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 4 Interventional Results available

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

NCT00660660
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
45
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 22, 2026, 12:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology

NCT01262755
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Functional Bowel Disorders
Interventions
Structured Interview
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

NCT01043185
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
AZD3355, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 22, 2026, 12:23 PM EDT
Active, not recruiting No phase listed Observational

Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease

NCT00260572
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Questionnaires to evaluate QOL, Questionnaires to evaluate heartburn and quality of life, Questionnaire to evaluate satisfaction with treatment, Questionnaire to evaluate presence or absence of pain
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01161602
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Pumosetrag, Placebo
Drug · Other
Lead sponsor
Edusa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Anaheim, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 22, 2026, 12:23 PM EDT
Completed No phase listed Observational

GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

NCT05875636
View directory record Official record
Conditions
Gastric Content Aspiration
Interventions
Esophagogastroduodenoscopy
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 12:23 PM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

NCT01265550
View directory record Official record
Conditions
GERD
Interventions
Nissen fundoplication, baclofen, Desipramine
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 22, 2026, 12:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Tooth Erosion in People With Esophagogastric Cancer

NCT05612048
View directory record Official record
Conditions
Esophagogastric Cancer
Interventions
Survey, Intra-oral camera, Optional Salvia sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 22, 2026, 12:23 PM EDT
Withdrawn Not applicable Interventional

PPI Versus Placebo in Severe Functional Heartburn

NCT00222989
View directory record Official record
Conditions
GERD
Interventions
PPI
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2100
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 22, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional Results available

Fexofenadine Use in Gastroesophageal Reflux Symptoms

NCT03425097
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Fexofenadine, Placebo - Cap
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 22, 2026, 12:23 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.

NCT00237068
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole; Solutab
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 22, 2026, 12:23 PM EDT
Recruiting Not applicable Interventional

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia

NCT06534359
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Gastroesophageal Reflux
Interventions
Transpyloric tube feeding, Gastric tube feeding
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn

NCT05363618
View directory record Official record
Conditions
Heartburn
Interventions
Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml), Placebo 1.4 ml
Dietary Supplement · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 3 Interventional

Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

NCT00195208
View directory record Official record
Conditions
Gastroesophageal Reflux, Esophagitis
Interventions
Pantoprazole for approximately 9 weeks
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 4 Interventional Results available

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

NCT00444145
View directory record Official record
Conditions
Larynx Disease, Gastroesophageal Reflux
Interventions
Prevacid, Esophageal and Laryngeal Biopsies
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Days to 11 Months
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 22, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants

NCT05366738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 22, 2026, 12:23 PM EDT